Researchers have developed a new way to target the toxic particles that destroy healthy brain cells in Alzheimer’s disease.
The Chemistry of Health building, a new facility dedicated to the use of chemical techniques to combat disease, in particular neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, was officially opened today in Cambridge.
Researchers have shown how cholesterol – a molecule normally linked with cardiovascular diseases – may also play an important role in the onset and progression of Alzheimer’s disease.
A new design of algae-powered fuel cells that is five times more efficient than existing plant and algal models, as well as being potentially more cost-effective to produce and practical to use, has been developed by researchers at the University of Cambridge.
Gifts totalling more than £32 million, together with government funds of over £17 million, have enabled the launch of a highly innovative Centre in Cambridge that is pioneering new approaches to understand and treat neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, motor neurone disease and frontotemporal dementia.
Researchers have manufactured microscopic versions of the cocoons spun by silkworms, which could be used to store sensitive proteins and other molecules for a wide range of uses.
It's over a hundred years since the first case of Alzheimer’s disease was diagnosed. Since then we’ve learned a great deal about the protein ‘tangles’ and ‘plaques’ that cause the disease. How close are we to having effective treatments – and could we even prevent dementia from occurring in the first place?
An approved anti-cancer drug successfully targets the first step in the toxic chain reaction that leads to Alzheimer’s disease, suggesting that treatments may be found to lower the risk of developing the neurodegenerative condition.
New funding will support fundamental research into the molecular processes underlying human disorders such as Alzheimer’s and Parkinson’s diseases, and enable new ways to combat them.
A molecular chaperone has been found to inhibit a key stage in the development of Alzheimer’s disease and break the toxic chain reaction that leads to the death of brain cells, a new study shows. The research provides an effective basis for searching for candidate molecules that could be used to treat the condition.